Abstract
This guideline provides a comprehensive overview of the management of localized rectal cancer, highlighting recent major advances in therapeutic strategies. Accurate staging remains essential, as it informs treatment decisions and facilitates risk assessment. A pivotal development in rectal cancer treatment is the adoption of total neoadjuvant therapy (TNT), which has demonstrated improved tumor response, reduced risk of systemic recurrence, and enhanced survival outcomes. This approach enables a "watch-and-wait" strategy and conservative management that may render surgery unnecessary and preserves rectal function in patients who achieve a complete clinical response. By emphasizing a structured approach to staging, multidisciplinary evaluation, and innovative treatment pathways, this guideline aims to improve outcomes while minimizing the morbidity associated with rectal cancer treatment.